Saint-Gobain Life Sciences and denovoMATRIX Announce Collaboration to Optimize New Product Development
DRESDEN, Germany, 9 November, 2021 / BioInformant / — denovoMATRIX GmbH and Saint-Gobain Life Sciences have entered into a Master Service Agreement focused on optimizing the performance of new products in development for adherent cell culture and harvest for autologous therapies. The relationship will further explore the synergy of consumable products from both parties and their positive effects for the therapeutic market.
Dejan Hušman, CEO of denovoMATRIX, commented “Integration of the latest technological innovations in the Cell Therapy space is essential to bring therapies to clinical trials and the mainstream as soon as possible. We are delighted to partner with Saint-Gobain Life Sciences to bring our technology platform to bear on the most critical challenges in autologous cell manufacturing.”
“We have found that the user experience is just as important as the product performance in new product development,” said Benjamin Le Quere, General Manager for Saint-Gobain Life Sciences’ Bioprocess Solutions Business Unit. “denovoMatrix is an ideal partner for us because of the technical capabilities they bring to this partnership. The feedback we receive from them will help ensure that our products are achieving the desired results, while being user-friendly for our customers.”
The companies expect to utilize both research and development and laboratory facilities from both companies, including in the United States and Germany. The companies will begin collaborating immediately.
By Cade Hildreth (CEO)